Logo image of LFCR

LIFECORE BIOMEDICAL INC (LFCR) Stock Analyst Ratings

NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD

6.83  +0.07 (+1.04%)

After market: 6.83 0 (0%)

Buy % Consensus

80

ChartMill assigns a Buy % Consensus number of 80% to LFCR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 10.2. This target is 49.34% above the current price.
LFCR was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about LFCR.
In the previous month the buy percentage consensus was at a similar level.
LFCR was analyzed by 8 analysts. More opinions would make the average more meaningful.

Related screens

LFCR Historical Analyst RatingsLFCR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -29 -26 -23 -20 -17 -14 -11 -8 -5 -2 2 4 6 8

Price Target & Forecast

Price Low Median Mean High 6.8310.1010.2010.2010.50 - 47.88% 49.34% 49.34% 53.73%

Related screens

LFCR Current Analyst RatingLFCR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2025-01-03 Stephens & Co. Reiterate Equal-Weight -> Equal-Weight
2024-11-22 Craig-Hallum Maintains Buy -> Buy
2024-09-05 Craig-Hallum Initiate Buy
2024-08-28 Barrington Research Downgrade Outperform -> Market Perform
2023-09-01 Barrington Research Maintains Outperform -> Outperform
2023-09-01 Stephens & Co. Maintains Equal-Weight -> Equal-Weight
2023-06-02 Barrington Research Maintains Outperform -> Outperform
2023-05-24 Barrington Research Maintains Outperform -> Outperform
2023-03-21 Barrington Research Maintains Outperform
2023-03-20 Barrington Research Maintains Outperform
2023-03-20 Stephens & Co. Downgrade Overweight -> Equal-Weight
2023-03-17 Stephens & Co. Reiterate Overweight